Christian Todd Nichols Sells 3,333 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS - Get Free Report) SVP Christian Todd Nichols sold 3,333 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $31.95, for a total transaction of $106,489.35. Following the completion of the transaction, the senior vice president now owns 89,542 shares of the company's stock, valued at approximately $2,860,866.90. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Christian Todd Nichols also recently made the following trade(s):

• On Tuesday, June 10th, Christian Todd Nichols sold 3,334 shares of Alkermes stock. The shares were sold at an average price of $31.09, for a total transaction of $103,654.06.

Alkermes Price Performance

Shares of ALKS traded down $0.95 on Friday, reaching $29.83. The company's stock had a trading volume of 2,207,105 shares, compared to its average volume of 1,734,585. The stock has a market capitalization of $4.92 billion, a P/E ratio of 13.75, a PEG ratio of 2.20 and a beta of 0.47. The stock's 50 day simple moving average is $29.63 and its two-hundred day simple moving average is $31.02. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The business had revenue of $306.51 million during the quarter, compared to analysts' expectations of $307.53 million. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The business's quarterly revenue was down 12.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. Analysts expect that Alkermes plc will post 1.31 earnings per share for the current year.

Hedge Funds Weigh In On Alkermes

Large investors have recently added to or reduced their stakes in the company. Natixis Advisors LLC lifted its holdings in Alkermes by 36.8% during the fourth quarter. Natixis Advisors LLC now owns 49,922 shares of the company's stock valued at $1,436,000 after purchasing an additional 13,432 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Alkermes by 147.4% during the fourth quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company's stock valued at $25,581,000 after purchasing an additional 529,962 shares in the last quarter. Savant Capital LLC lifted its holdings in Alkermes by 11.6% during the fourth quarter. Savant Capital LLC now owns 11,075 shares of the company's stock valued at $319,000 after purchasing an additional 1,152 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Alkermes by 558.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after purchasing an additional 2,502 shares in the last quarter. Finally, Ieq Capital LLC purchased a new position in Alkermes during the fourth quarter valued at approximately $1,057,000. Hedge funds and other institutional investors own 95.21% of the company's stock.

Wall Street Analysts Forecast Growth

ALKS has been the subject of a number of analyst reports. Cantor Fitzgerald upgraded shares of Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. HC Wainwright reiterated a "neutral" rating on shares of Alkermes in a research note on Friday, May 2nd. Robert W. Baird lifted their price target on shares of Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group lifted their price target on shares of Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $38.85.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.